ChatGPT

Perplexity

Gemini

Claude

Grok

The Fluent system is the latest innovation in Fluid Management from Hologic, Inc. This app takes you through system setup, operation, troubleshooting guides and videos.

Una oficina 24/7 en tus dispositivos móviles donde podrás disfrutar de múltiples beneficios.

Es muy fácil de usar; Ingrese a un mundo de operaciones desde su dispositivo móvil.

Opcional autenticació

We view everyone through a talent-first lens free from unconscious judgments, recognizing that our employees' capabilities are our key differentiator in the market.

Talent-First Approach

We are guided by a deep sense of purpose to improve women's health, ensuring every innovation delivers meaningful clinical value and better patient outcomes.

Purpose-Driven Innovation

We trust each other to be vulnerable, creating a psychologically safe environment where team members can challenge ideas and drive innovation.

Trust & Vulnerability

We commit our energy to the greater good of the team, hold ourselves accountable to high standards, and focus on collective results over individual recognition.

Collective Accountability

We foster exceptional employee engagement, having risen from the 36th to the 96th percentile in Gallup's global company database, reflecting our commitment to workplace excellence.

World-Class Engagement

Hologic is a leading medical technology company focused on women's health, developing diagnostic products, medical imaging systems, and surgical solutions across breast health, diagnostics, gynecological surgical, and skeletal health segments.

Stephen P. MacMillan

Chairman, President & Chief Executive Officer

Essex D. Mitchell

Chief Operating Officer

Karleen M. Oberton

Chief Financial Officer

Paul Malenchini

Chief Information Officer

Anne Liddy

General Counsel

Alana Dros

Vice President, Human Resources

Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.

Hologic's flagship breast imaging platform combines 3D mammography technology with Genius AI Detection, a deep-learning algorithm that aids radiologists in breast cancer detection. The system detects 20-65% more invasive breast cancers than conventional 2D mammograms and runs directly on the acquisition workstation without requiring separate servers. The technology includes the Selenia Dimensions and 3Dimensions mammography systems.

Genius 3D Mammography & AI Detection

The ThinPrep Pap test is the world's most widely used cervical cancer screening test, acquired through the Cytyc merger in 2007. The Genius Digital Diagnostics System with Genius Cervical AI algorithm provides FDA-cleared automated cervical cancer screening using artificial intelligence to enhance diagnostic accuracy for HPV and cervical abnormalities.

ThinPrep Pap Test & Cervical Cancer Screening

Hologic offers comprehensive breast biopsy solutions including the ATEC (Automatic Tissue Excision and Collection) Breast Biopsy System, Multicare Platinum Prone Biopsy System, and stereotactic breast biopsy platforms. The 2024 Endomagnetics acquisition added Magseed markers, Magtrace lymphatic tracing, and the Sentimag platform for advanced breast surgery guidance.

Breast Biopsy & Surgical Guidance Systems

Through the Gen-Probe and Third Wave Technologies acquisitions, Hologic offers molecular diagnostic instrumentation for infectious disease testing, HPV screening, and women's health diagnostics. The portfolio includes rapid testing platforms and automated systems for high-throughput clinical laboratories.

Molecular Diagnostics & HPV Testing

Hologic's gynecological surgical portfolio includes the NovaSure endometrial ablation system, MyoSure tissue removal system, and the recently acquired Sonata transcervical fibroid treatment system. Sonata is the first FDA-cleared device combining real-time intrauterine ultrasound guidance with targeted radiofrequency ablation for treating uterine fibroids without incisions.

GYN Surgical Solutions (NovaSure, MyoSure, Sonata)

Hologic's original product line, QDR Bone Densitometer Systems remain the gold standard for assessing bone density, fracture risk, and body composition. Hologic introduced the first DXA (dual-energy X-ray absorptiometry) system to measure bone density, and the technology continues to serve as the foundation for osteoporosis diagnosis worldwide.

QDR Bone Densitometry Systems

Hologic provides mini C-arm imaging systems for extremities imaging, offering superior positioning, enhanced imaging quality, and easy handling to meet the demands of orthopedic and surgical procedures requiring real-time fluoroscopic guidance.

Mini C-Arm Imaging Systems

Hologic reported strong Q4 fiscal 2024 results with revenue of $987.9 million and non-GAAP EPS of $1.01, concluding the year with $4.03 billion in total revenue. The company demonstrated 4.5% total revenue growth in Q4 and maintained strong cash flow generation with $367.1 million in operating cash flow for the quarter.

Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024

Hologic completed the acquisition of Endomagnetics Ltd, a privately held developer of breast cancer surgery technologies, for approximately $310 million. The acquisition adds Magseed marker, Magtrace lymphatic tracing injectable, and Sentimag platform to Hologic's breast health portfolio, strengthening its position in surgical guidance solutions.

Hologic Completes Acquisition of Endomagnetics

Hologic announced an agreement to acquire Gynesonics for $350 million, adding the Sonata transcervical fibroid treatment system to its GYN Surgical portfolio. The FDA-cleared Sonata system combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation to treat uterine fibroids without incisions, addressing a significant unmet need in women's health.

Hologic to Acquire Gynesonics for $350 Million

Hologic was recognized as a Top Workplace by Forbes and Fortune based on employee feedback measuring trust in management, connection with colleagues, and loyalty to the company. The recognition reflects Hologic's achievement of 90% employee satisfaction ratings and world-class engagement scores, ranking in the 97th percentile of Gallup's global company database.

Hologic Recognized as Top Workplace by Forbes and Fortune

Private equity firms Blackstone and TPG, along with minority investors Abu Dhabi Investment Authority and Singapore GIC, announced an agreement to acquire Hologic for $18.3 billion including debt, representing a 46% premium to the closing price. The transaction will take Hologic private to accelerate innovation and strategic investments in women's health technology.

Blackstone and TPG to Acquire Hologic for $18.3 Billion

Hologic completed the acquisition of Gynesonics, Inc. in early January 2025, integrating the Sonata transcervical fibroid treatment system into its GYN Surgical portfolio. The acquisition strengthens Hologic's position in minimally invasive gynecological surgical solutions and expands treatment options for women with uterine fibroids.

Hologic Completes Gynesonics Acquisition

Hologic published its comprehensive Sustainability Report detailing the company's environmental, social, and governance (ESG) initiatives, including expanded environmental ambitions, diversity and inclusion programs, and commitments to reducing the company's carbon footprint. The report highlights Hologic's progress in sustainable manufacturing and corporate responsibility in advancing women's health globally.

Hologic Details Environmental and Social Governance Efforts in New Sustainability Report

Per Jon Wertheim, WTA is on the verge of closing a deal with a car company to replace Hologic as their title partner sponsor

Toxic Leadership, Fake Positivity, and Zero Accountability- Hologic

Life Inside Hologic: Toxic Leadership, Retaliation, and Patient Safety Risks

Illumina, Hologic, Thermo… who’s still leading, and who's worth working for?

Hologic

Hologic + Blackstone + TPG

Hologic Marketing

Standard PCR and Aptima Hologic TMA

MedicalDevices

tennis

Whistleblowers

biotech

private_equity

MycoplasmaGenitalium

HOLOGIC INC

X-Ray Apparatus & Tubes & Related Irradiation Apparatus

Jay A. Stein and S. David Ellenbogen founded Hologic in Bedford, Massachusetts with 12 employees and a mission to develop an X-ray bone densitometer for osteoporosis diagnosis, establishing the foundation for what would become a women's health technology leader.

Company Founded

Hologic went public on the NASDAQ stock exchange, providing capital for research and development investments that would enable the company's expansion beyond bone densitometry into broader medical imaging markets.

Initial Public Offering

Hologic completed the transformational merger with Cytyc Corporation, fundamentally shifting from primarily an imaging company to a diversified medical technology leader. The acquisition added the ThinPrep Pap test and breast health technologies to Hologic's portfolio.

Cytyc Corporation Merger

Hologic acquired Third Wave Technologies, gaining a foothold in molecular diagnostics and HPV testing markets. This acquisition strengthened Hologic's position in cervical cancer screening and molecular diagnostic capabilities.

Third Wave Technologies Acquisition

The FDA approved Hologic's Selenia Dimensions 3D Mammography system, revolutionizing breast cancer screening technology. This breakthrough product established Hologic as the leader in breast health technology with superior cancer detection rates.

FDA Approval of 3D Mammography

Hologic completed the acquisition of Gen-Probe for $3.7 billion, creating what company officials called the largest diagnostics company focused on women's health. The deal significantly expanded Hologic's molecular diagnostics capabilities and market reach.

Gen-Probe Acquisition

Stephen P. MacMillan joined Hologic as President and CEO, bringing extensive medical device industry experience from his tenure as CEO of Stryker Corporation. His leadership would drive strategic focus and operational improvements.

Stephen MacMillan Appointed CEO

Hologic completed the acquisition of Mobidiag for $795 million, expanding its molecular diagnostics portfolio with rapid syndromic testing capabilities. The acquisition strengthened Hologic's position in infectious disease diagnostics.

Mobidiag Acquisition

Hologic completed the acquisition of Endomagnetics Ltd for approximately $310 million, adding Magseed marker, Magtrace lymphatic tracing injectable, and Sentimag platform technologies for breast surgery guidance.

Endomagnetics Acquisition

Hologic closed fiscal year 2024 with record revenue of $4.03 billion and non-GAAP EPS of $4.08, demonstrating strong performance across all business segments and impacting 193 million lives worldwide with its technologies.

Record Fiscal Year Performance

Hologic announced the acquisition of Gynesonics for $350 million, adding the Sonata transcervical fibroid treatment system to its GYN Surgical portfolio. The FDA-cleared system uses ultrasound guidance and radiofrequency energy to treat uterine fibroids.

Gynesonics Acquisition Announced

Hologic completed the acquisition of Gynesonics in early January 2025, integrating the Sonata fibroid treatment system into its product portfolio and strengthening its position in gynecological surgical solutions.

Gynesonics Acquisition Completed

Private equity firms Blackstone and TPG announced an agreement to acquire Hologic for $18.3 billion including debt, taking the company private. The transaction values the company at a significant premium and aims to accelerate innovation in women's health.

Hologic vs Oura

Hologic

About

Oura

About

Also Compare

Track AI Visibility in Real Time